Inappropriate Drug Use in People with Cognitive Impairment and Dementia: A Systematic Review

Kristina Johnell*

Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden

Abstract: The aim of this systematic review was to identify, assess and summarize studies about potentially inappropriate drug use (IDU) in cognitive impairment and dementia and to present findings about whether cognitive impairment and dementia are associated with IDU. The search was made in Medline/PubMed using free terms in the title or abstract. The inclusion criteria were: English language, published until 1 March 2014, original quantitative study and assessment of overall IDU with a consensus based summarized measure. Exclusion criteria were: focus on specific patient group (other than cognitive impairment or dementia), focus on specific drug class and failure to present a prevalence measure of IDU or an effect estimate (i.e. odds ratio). Of the initial 182 studies found in Medline, 22 articles fulfilled the criteria. Most studies used the Beers criteria for assessment of IDU. Prevalence of IDU among individuals with cognitive impairment or dementia ranged from 10.2% to 56.4% and was higher in nursing home settings than in community-dwelling samples. Most studies reported a lower likelihood of IDU in case of cognitive impairment or dementia. To conclude, IDU is highly prevalent among persons with cognitive impairment and dementia, although these conditions seem to be associated with a lower probability of IDU. This might reflect an awareness among clinicians of cautious prescribing to this vulnerable group of patients. More studies on large cohorts of persons with cognitive impairment and dementia are needed to draw conclusions about optimal drug prescribing to this frail group of older persons.

Keywords: Cognitive impairment, dementia, inappropriate drug use, systematic review.

BACKGROUND

The worldwide aging of the population imposes great demands on the society and health care systems, where the increased use of pharmaceutical drugs is an important challenge. At the individual level, the challenge is to balance problems related to drug use without denying older people potentially valuable drug therapy. At the societal level, the challenge is to minimize drug-related illness, hospitalizations and associated costs [1, 2].

Older people often have multiple diseases and impairments and aging also leads to changes in both the turnover of drugs in the body (pharmacokinetics) and their actions (pharmacodynamics), which result in prolonged action and stronger effects of many drugs [3]. At the same time, drug use extensively among older people and polypharmacy (i.e. concurrent use of many drugs) is common. In Sweden, 39% of community-dwelling and 76% of institutionalized persons aged ≥ 65 years are exposed to polypharmacy (≥5 drugs) [4]. There is a lack of evidence for this kind of drug therapy because clinical drug trials often exclude older patients with polypharmacy and multiple comorbidities [5]. Hence, this lack of evidence leaves the clinician with difficult decisions about risks and benefits of drug treatment in advanced ages. Taken together, older people have the greatest risks of adverse drug reactions [6].

Particularly vulnerable are dementia patients who are especially sensitive to adverse effects of CNS-acting drugs [7]. Dementia causes specific disease-related brain-changes that lead to increased sensitivity to centrally acting drugs and cognitive deficits further complicates drug treatment [3]. There is a high risk of both under- and over treatment due to communication problems and psychiatric and behavioral changes. This might lead to inappropriate treatment with psychotropic drugs [8] and a neglect of somatic conditions [9]. However, relatively few studies have assessed the quality of prescription in people with dementia.

An important concept of quality of drug therapy in old age is potentially inappropriate drug use (IDU), which is defined as drug therapy that poses potential risks that outweigh potential benefits [10]. There are many measures of IDU in older people and these are explicit measures generally based on consensus panels [11]. Some of the most common measures of IDU include the Beers criteria (originally from 1991) [10] and the Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP) criteria developed in 2008 [12]. Holmes has also developed a specific tool for assessment of inappropriate drug prescribing in advanced dementia for patients where the primary goal is palliation of symptoms [13].

IDU is common in older people (ranging from about 12% to 63%) [11], particularly in institutions where the frailest
older persons reside [14], and have been associated with adverse outcomes such as hospitalization and mortality [15, 16]. However, there is tentative support for prevention of the majority of these problems through educational outreach and improved knowledge about drug prescribing for older people [17]. Nonetheless, IDU in persons with cognitive impairment or dementia is an understudied area. The present review may be the first systematic review on this topic.

The objective of this systematic review was to identify, assess and summarize available studies about potential IDU in cognitive impairment and dementia and to present findings about whether cognitive impairment and dementia are associated with IDU.

METHODS

Search Strategy

The search for studies was made by one researcher (KJ) in the Medline electronic database, using the PubMed interface. The following free terms were used: “inappropriate”, “dementia”, “cognitive impairment”, “Alzheimer”, “drug”, “drugs”, “medication” and “medications” in the title or abstract.

INCLUSION CRITERIA

The articles had to be published in English up until 1 March 2014. Only indexed original research papers were included. They also had to have a quantitative design, analyze overall IDU (i.e. not specific drug classes such as psychotropics) with an explicit consensus based summarized measure of IDU.

EXCLUSION CRITERIA

Articles were excluded if they focused on specific patient groups (e.g. fallers, cardiovascular patients) or specific drug classes. They were also excluded if they failed to present a prevalence measure for IDU or an effect estimate (i.e. odds ratio [OR] with 95% confidence intervals [CIs]) for the association between cognitive impairment or dementia and IDU.

SELECTION OF STUDIES

After the initial search, abstracts of the papers that included the topic of IDU in cognitive impairment or dementia were retrieved. Thereafter, the inclusion and exclusion criteria were applied. Finally, the articles that fulfilled these criteria were retrieved in full-text.

Papers identified through manual search of reference lists of selected papers also underwent assessment according to the established inclusion and exclusion criteria.

DATA EXTRACTION

The following data were extracted from the papers that fulfilled the above mentioned criteria: country, population characteristics (including assessment of dementia and

Fig. (1). Flowchart of systematic article search.
Table 1. Prevalence of inappropriate drug use (IDU) in persons with cognitive impairment or dementia.

| Reference, Year | Country | Population Characteristics, Sample Size and Assessment of Dementia or Cognitive Impairment | Assessment of Drug Use | Criteria for IDU | Prevalence (at least one IDU) |
|-----------------|---------|------------------------------------------------------------------------------------------|------------------------|----------------|-------------------------------|
| Montastruc et al., 2013 [23] | France | Community-dwelling Alzheimer patients assessed by DSM-IV and NINCDS-ADRDA criteria for Alzheimer-type dementia at mild to moderate stage (n=684) | Caregiver reports | Laroche list | 46.8% |
| Fiss et al., 2013 [20] | Germany | Community-dwelling persons with cognitive impairment assessed by DemTect screening (n=111) | In-home interviews | PRISCUS list | 19.8% |
| Koyama et al., 2013 [21] | USA | Community-dwelling women with dementia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (n=260) | Self-reported drug use within the past 30 days | Beers list | 33.1% |
| Parsons et al., 2012 [32] | UK | Older people with dementia (derived from medical records) in care homes (n=119) | Medical records | STOPP criteria | 46.2% |
| Bosboom et al., 2012 [29] | Australia | Dementia patients (in medical records) in residential aged care facilities (n=226) | Medical records | Modified Beers list | 56.4% |
| Colloca et al., 2012 [30] | SHELTER (8 European countries) | Nursing home residents with severe cognitive impairment assessed by the Cognitive Performance Scale (CPS) (n=1449) | Medical records | Holmes list | 44.9% |
| Lau et al., 2011 [27] | USA | Community-dwelling older adults with dementia assessed by the Clinical Dementia Rating (CDR) scale (n=1994) | Self-reported drug use within the last 2 weeks | Beers list | 16.2% |
| Tjia et al., 2010 [34] | USA | Nursing home residents with advanced dementia assessed by the Cognitive Performance Scale (n=323) | Medical records | Holmes list | 37.5% |
| Weston et al., 2010 [28] | USA | Patients clinically diagnosed with mild cognitive impairment (n=689) | Self-report and caregiver report | Beers list | 20.8% |
| Lau et al., 2010 [26] | USA | Community-dwelling persons with dementia assessed by the Clinical Dementia Rating (CDR) scale (n=2665) | Self-report | Beers list | 15.0% |
| Holmes et al., 2008 [13] | USA | Patients with advanced dementia assessed by the Functional Assessment Stages (FAST) in long-term care (n=34) | Nursing home records and proxy interviews | Holmes list | 29.4% |
| Wawruch et al., 2008 [36] | Slovakia | Hospitalized dementia patients (dementia diagnosis from medical records) (n=89) | Medical records | Beers list | 22.4% |
| Raivio et al., 2006 [33] | Finland | Hospitalized patients and nursing home residents with dementia based on the Diagnostic and Statistical Manual of Mental Disorders (4th edition) [DSM-IV] criteria (n=255) | Medical records | Beers list | 36.9% |
| Fialova et al., 2005 [25] | Eight European countries | Home care patients with cognitive impairment assessed by the Cognitive Performance Scale (CPS) (n=773) | Self-reported, caregiver reported and medical records | Beers and McLeod list | 20.7% |
| Zuckerman et al., 2005 [35] | USA | Dementia patients admitted to nursing home (n=334). Dementia diagnosis based on Diagnostic and Statistical Manual of Mental Disorders (3rd edition) | Prescription claims | Beers list | 20% |
| Ay et al., 2005 [24] | Turkey | Community-dwelling persons with dementia assessed by the Mini Mental State Examination (MMSE) (n=322) | Self-reported drug use in the previous three weeks | Beers list | 10.2% |
| Nygaard et al., 2003 [31] | Norway | Cognitively impaired (assessed by the Clinical Dementia Rating (CDR)) nursing home residents (n=870) | Medical records | Modified Beers list | 21.6% |

cognitive impairment), assessment of drug use, criteria for IDU, prevalence of IDU and effect estimate (i.e. OR with 95% CI) for the association between cognitive impairment or dementia and IDU. In some instances, the prevalence of IDU was not available and then had to be calculated. Adjusted ORs were extracted where possible.
RESULTS

The search strategy resulted in 182 papers in Medline. Fig. 1 displays the selection process in a flow chart diagram. After initial screening of title and/or abstract, 38 abstracts about IDU and cognitive impairment or dementia were collected. These abstracts were then assessed according to the inclusion and exclusion criteria and resulted in inclusion of 20 papers that were retrieved in full-text. Two more papers were also added after manual search of reference lists of the selected papers after fulfillment of inclusion and exclusion criteria.

The publication of studies increased over time; there was one paper published in 2002 (earliest included paper) [18] and five in 2013 [19-23] (Tables 1 and 2).

Table 1 shows the 17 included articles that reported prevalence of IDU in persons with cognitive impairment or dementia. The studies were conducted in Europe, Asia, USA and Australia. The population characteristics varied considerably in setting and sample size. Eight studies were based on community-dwelling samples [20, 21, 23-28], 8 conducted in nursing homes [13, 29-35] and 2 in the hospital setting [33, 36]. The assessment of drug use was made through medical records in the nursing home and hospital settings, whereas self-reported drug use was collected in the community-dwelling setting. Sample size of individuals with cognitive impairment or dementia ranged from 34 [13] to 2,665 [26]. Five studies were based on people with cognitive impairment (mild to severe) and 12 on dementia patients. Most studies used the Beers criteria (64.7%; 11/17) [21, 24-29, 31, 33, 35, 36]. Three studies used the Holmes criteria for prescribing in advanced dementia [13, 30, 34]. Prevalence of IDU among individuals with cognitive impairment or dementia ranged from 10.2% to 56.4% (Table 1). Most studies, however, reported a prevalence of IDU between 20 to 50% (76.5%; 13/17). The lowest prevalence was reported from Turkey [24] and the highest from Australia [29]. Yet, the limited number of studies prohibited comparisons between countries. Prevalence was higher in nursing home settings than in community-dwelling samples. Also, the three studies that used the Holmes criteria for prescribing in advanced dementia [13, 30, 34] were among those that reported the highest prevalence of IDU (29.4%-44.9%). Common IDU in advanced dementia were lipid-lowering agents, antiplatelet agents (excluding acetylsalicylic acid), anti-dementia drugs and antispasmodics [13, 30, 34].

Table 2 shows the 8 included articles that investigated the association between cognitive impairment or dementia and IDU. Three of these studies [24, 31, 35] were also included in Table 1.

The studies included in Table 2 were based on people both with and without cognitive impairment or dementia and had, thus, larger sample sizes than the prevalence studies in...
Table 1. The represented countries and settings were, however, similar to the prevalence studies. Also here were the Beers criteria the most commonly used measure of IDU (75%; 6/8) [18, 24, 31, 35, 37, 38].

Six [18, 19, 22, 31, 37, 38] of the 8 articles reported a lower likelihood of IDU in case of cognitive impairment or dementia (Table 2). The remaining 2 papers [24, 35] showed no statistically significant association (with wide confidence intervals) between cognitive impairment or dementia and IDU. Hence, no study reported a positive association.

DISCUSSION

This review endeavored to compile and contribute to the knowledge about IDU in people with cognitive impairment and dementia by systematically identifying, assessing and summarizing available studies on the topic. The findings of this review suggest that the prevalence of IDU in people with cognitive impairment and dementia is high. Nevertheless, these conditions seem to be associated with a lower likelihood of IDU.

The reported prevalence of IDU varied greatly between studies, ranging from 10.2% to 56.4%, although most studies reported a prevalence between 20 to 50%. This is in line with a recent review of IDU in general populations of older people that reported a range of 11.5% to 62.5% [11]. The variation in occurrence of IDU may be explained by differences in assessment of IDU, study design, setting and population characteristics. Indeed, drugs included in explicit criteria for IDU (e.g. Beers list) may have limited availability in other countries outside of where they were originally established [39]. Also, IDU was more common in the institutional than in the community-dwelling setting. This finding is consistent with a previous investigation of older people in which institutionalization was identified as a potential risk factor for IDU [14]. Further, most studies used the Beers criteria for assessment of IDU [10]. These studies reported a variation in prevalence of IDU between 10% and 56%. The second most commonly used assessment tool was the Holmes list, which is intended for use in patients with advanced dementia where the primary goal is palliation of symptoms [13]. The prevalence of IDU in these studies was high and ranged between 29% and 45%. Hence, the population characteristics and the actual assessment method of IDU have a great impact on the reported prevalence.

Persons with cognitive impairment or dementia are particularly susceptible to adverse effects of drugs and communication problems further complicates drug treatment [7]. Hence, drug prescribing to this vulnerable group of patients should be made very cautiously and ideally be adjusted and reconsidered as the disease progresses. In the early stages of disease, life prolonging treatments are indicated, where as drugs that reduce suffering is of highest priority in the advanced stages [34]. The clinician is faced with many difficult decisions and little evidence to rely on. Thus, more research is needed on how to best treat patients with cognitive impairment and dementia across the different stages of disease [40].

Despite the high exposure to IDU, cognitive impairment and dementia were associated with a lower probability of IDU in most studies. No study reported a positive association between cognitive impairment or dementia and IDU. However, the same criteria for IDU were used for patients with and without cognitive impairment or dementia, although there may be a difference in which medications should be regarded as appropriate or inappropriate in these two groups [13]. In particular, studies have reported higher prevalence of anticholinergic and sedative drugs in persons with cognitive impairment and dementia [41, 42], although these drugs are of particular concern in this population [7].

This consistent finding of an inverse or no effect of cognitive impairment or dementia on IDU is difficult to explain and probably multifactorial. Mann et al. found in their study that it was neuropsychiatric symptoms rather than cognitive impairment that provoked IDU [22]. Many of the psychototropic drugs that are used for treatment of neuropsychiatric symptoms are indeed considered as inappropriate prescribing [43]. Sloane et al. argue that their finding of an independent relationship between dementia and absence of IDU may be because conditions or symptoms that are treated with IDU are rarely voiced by persons with dementia and give the example of pain medications [18]. This might also hold true for cardiovascular drugs, as persons with dementia have been found to have less potential drug-disease interactions involving cardiovascular agents than those without dementia [44]. Perri et al. suggest that possible explanations include physicians’ vigilance in prescribing to patients with reduced cognitive capacity in fear of further cognitive impairment from adverse drug effects [38]. In this sense, the consistent finding of an inverse or no effect of cognitive impairment or dementia on IDU may reflect appropriate prescription to frail older patients and may be a sign of good clinical practice [37].

This review has some limitations. First, the search strategy, application of inclusion and exclusion criteria and selection of studies might have resulted in missed articles that were not identified or incorrectly excluded. The search was made in one database (Medline/PubMed), only included articles published in English and with an explicit consensus based summarized measure of IDU (i.e. not on other dimensions of suboptimal drug use, such as drug-drug interactions). However, 22 articles in the final sample may be regarded as a fairly large number in comparison with other reviews on related topics [11].

Second, the systematic search and assessment of inclusion and exclusion criteria were made by one person, which may increase the risk of bias.

Third, this review focused on prevalence of IDU and on the possible association between cognitive impairment or dementia and IDU. Hence, neither interventions for reduction of IDU [17] nor outcomes of IDU were considered [2]. Reviews about these topics in cognitive impairment and dementia are needed, although they might be difficult to complete due to limited number of published studies.

Finally, potentially IDU is not equal to actual IDU given that a drug judged to be inappropriate by definition may sometimes be justified and indicated for the individual patient [45].
CONCLUSIONS

IDU is highly prevalent among persons with cognitive impairment and dementia. This is of concern given that these persons are highly susceptible to adverse drug reactions and may have problems with communicating adverse effects.

Still, cognitive impairment and dementia were associated with a lower risk of IDU. This might reflect an awareness among clinicians of cautious prescription to this vulnerable group of patients. More studies on large cohorts of persons with cognitive impairment and dementia are needed to draw conclusions about optimal drug prescription to this frail group of older persons.

CONFLICT OF INTEREST

This research was supported financially by a grant from the Swedish Research Council. The author has no conflicts of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Shamliyan T. Adverse drug effects in hospitalized elderly data from the healthcare cost and utilization project. Clin Pharmacol 2010; 2: 41-63.

[2] Chiatti C, Bustacchini S, Furneri G et al. The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people a systematic review. Drug Saf 2012; 35 (1): 73-87.

[3] Shi S, Morike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008; 64: 183-99.

[4] Johnell K, Fastbom J. Comparison of Prescription Drug Use between Community Dwelling and Institutionalized Elderly in Sweden. Drugs Aging 2012; 29: 751-8.

[5] Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc 2010; 58: 1791-7.

[6] Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Saf 2012; 35 (1): 29-45.

[7] Bell JS, Mezranzi C, Blacker N et al. Anticholinergic and sedative medicines prescribing considerations for people with dementia. Aust Fam Physician 2012; 41: 45-9.

[8] Haasum Y, Fastbom J, Fratiglioni L, Kareholt I, Johnell K. Pain treatment in elderly persons with and without dementia: a population based study of institutionalized and home dwelling elderly. Drugs Aging 2011; 28: 283-93.

[9] Haasum Y, Fastbom J, Fratiglioni L, Johnell K. Undertreatment of osteoporosis in persons with dementia A population based study. Osteoporos Int 2012; 23: 1061-8.

[10] Beers MH, Ouslander JG, Rollinger I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151: 1825-32.

[11] Guaraldo L, Cano FG, Damasceno GS, Rozenfeld S. Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC Geriatr 2011; 11: 79.

[12] Gallagher P, O'Mahony D. Screening Tool of Older Persons' potentially inappropriate Prescriptions application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing 2008; 37: 673-9.

[13] Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox HD, Dale W. Integrating palliative medicine into the care of persons with advanced dementia identifying appropriate medication use. J Am Geriatr Soc 2008; 56: 1306-11.

[14] Haasum Y, Fastbom J, Johnell K. Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide register based study. Ann Pharmacother 2012; 46: 339-46.

[15] Gosch M, Wortz M, Nicholas JA, Doshi HK, Kamenderman C, Lechleitner M. Inappropriate Prescribing as a Predictor for Long Term Mortality after Hip Fracture. Gerontology 2014; 60 (2): 114-22.

[16] Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality a population based study of the very old. Drugs Aging 2005; 22: 69-82.

[17] Forsellund L, Eike MC, Gjerberg E, Vist GE. Effect of interventions to reduce potentially inappropriate use of drugs in nursing homes: a systematic review of randomised controlled trials. BMC Geriatr 2011; 11: 16.

[18] Sloane PD, Zimmerman S, Brown LC, Ives TJ, Walsh JF. Inappropriate medication prescribing in residential care/assisted living facilities. Am J Geriatr Soc 2002; 50: 1001-11.

[19] Hoda D, Cai S, Gidmark S, Thomas K, Intrator O. Potentially inappropriate medication use in veterans residing in community living centers have we gotten better. J Am Geriatr Soc 2013; 61: 1994-9.

[20] Fiss T, Thyrion JR, Fendrich K, van den Berg N, Hoffmann W. Cognitive impairment in primary ambulatory health care pharmacotherapy and the use of potentially inappropriate medicine. Int J Geriatr Psychiatry 2013; 28: 173-81.

[21] Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Ten-year trajectory of potentially inappropriate medications in very old women importance of cognitive status. J Am Geriatr Soc 2013; 61: 256-63.

[22] Mann E, Haastert B, Bohndorfer B, et al. Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents secondary analysis of a cross sectional study. Wien Klin Wochenschr 2013; 125: 180-8.

[23] Montastruc F, Gardette V, Cantet C, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL. FR cohort be aware of atropinic and benzodiazepine drugs. Eur J Clin Pharmacol 2013; 69 (8): 1589-97.

[24] Ay P, Akici A, Harmanc H. Drug utilization and potentially inappropriate drug use in elderly residents of a community in Istanbul. Int J Clin Pharmacol Ther 2005; 43: 195-202.

[25] Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293: 1348-58.

[26] Lau DT, Mercaldo ND, Harris AT, Trtitschuk E, Shega J, Weintraub S. Polypharmacy and potentially inappropriate medication use among community dwelling elders with dementia. Alzheimer Dis Assoc Disord 2010; 24: 56-63.

[27] Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community dwelling older adults with dementia. Am J Alzheimers Dis Other Demen 2011; 26: 606-15.

[28] Weston AL, Weinstein AM, Barton C, Yaffe K. Potentially inappropriate medication use in older adults with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2010; 65: 318-21.

[29] Adissen F, Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of Potentially Harmful Medications and Health Related Quality of Life among People with Dementia Living in Residential Aged Care Facilities. Dement Geriatr Cogn Dis Extra 2012; 2: 361-71.

[30] Colloca G, Tosato M, Vetrano DL, et al. Inappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter study 2012; 7: e46669.

[31] Nygaard HA, Naik M, Ruths S, Straand J. Nursing-home residents and their drug use: a comparison between mentally intact and mentally impaired residents. The Bergen district nursing home (BEDNURS) study. Eur J Clin Pharmacol 2003; 59: 258-63.

[32] Persson C, Johnston S, Mathie E, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging 2012; 29: 143-55.

[33] Rainio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging 2006; 23: 333-43.

[34] Ija J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc 2010; 58: 880-8.

[35] Zuckerman IH, Hernandez JJ, Gruber-Baldini AL, et al. Potentially inappropriate prescribing before and after nursing home admission among patients with and without dementia. Am J Geriatr Pharmacother 2005; 3: 246-54.
[36] Wawruch M, Fialova D, Zikavská M, et al. Factors influencing the use of potentially inappropriate medication in older patients in Slovakia. J Clin Pharm Ther 2008; 33: 381-92.

[37] Onder G, Landi F, Cesari M, Gambassi G, Carbonin P, Bernabei R. Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly. Eur J Clin Pharmacol 2003; 59: 157-62.

[38] Perri M 3rd, Menon AM, Deshpande AD, et al. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother 2005; 39: 405-11.

[39] Leikola S, Dimitrow M, Lyles A, Pitkala K, Airaksinen M. Potentially inappropriate medication use among finnish non-institutionalized people aged >/=65 years: a register-based, cross-sectional, national study. Drugs Aging 2011; 28: 227-36.

[40] Fereshtehnejad SM, Johnell K, Eriksdotter M. Anti-Dementia Drugs and Co-Medication Among Patients with Alzheimer's Disease: Investigating Real-World Drug Use in Clinical Practice Using the Swedish Dementia Quality Registry. Drugs Aging 2014; 31: 215-24.

[41] Gnjidic D, Hilmer SN, Hartikainen S, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study. PLoS One 2014; 9: e83224.

[42] Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700 000 elderly patients. Drugs Aging 2008; 25: 871-7.

[43] Johnell K, Religa D, Eriksdotter M. Differences in Drug Therapy between Dementia Disorders in the Swedish Dementia Registry: A Nationwide Study of over 7,000 Patients. Dement Geriatr Cogn Disord 2013; 35: 239-48.

[44] Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc 2001; 49: 277-83.

[45] Johnell K, Fastbom J, Rosen M, Leimanis A. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007; 41: 1243-8.